Examination of the metabolic status of primitive, stem cell-enriched CD34+ or CD34+ CD38– cells compared to differentiated CD34– cells from CML patients showed an increased oxidative status in the CML stem cell fraction. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.